Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

319P - Enfortumab vedotin with or without pembrolizumab in Asian patients with metastatic urothelial carcinoma: The preliminary territory-wide real-world experience in Hong Kong

Date

07 Dec 2024

Session

Poster Display session

Presenters

Darren Poon

Citation

Annals of Oncology (2024) 35 (suppl_4): S1505-S1530. 10.1016/annonc/annonc1689

Authors

D.M.C. Poon1, K.C.W. Wong2, K.K.S. Wong3, B.C.W. Li4

Author affiliations

  • 1 Comprehensive Oncology Center, Hong Kong Sanatorium & Hospital, 001 - Hong Kong/HK
  • 2 Department Of Clinical Oncology, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, 852 - Hong Kong/HK
  • 3 Department Of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 001 - Hong Kong/HK
  • 4 Medicine Department, A1 Doctor Office, Queen Mary Hospital, Hong Kong/HK

Resources

This content is available to ESMO members and event participants.

Abstract 319P

Background

Enfortumab vedotin (EV), as monotherapy (mono) or combined with pembrolizumab (P), has shown overall survival (OS) benefit in metastatic urothelial carcinoma (mUC) patients (pts), regardless of prior systemic therapy. Despite positive data from pivotal trials, the real-life experience with EV in Asian pts, particularly treatment-related adverse events (TRAEs), remains uncertain. This is the first report on the preliminary efficacy and tolerability of EV±P in real-world mUC pts in Hong Kong (HK).

Methods

We retrospectively collected demographics, treatment response, TRAEs, and other clinical data on mUC pts treated with EV±P in public/private hospitals in HK from June 2023–May 2024. TRAEs were reported per the CTCAE version 5.0 criteria. Objective response rates (ORRs) were assessed per the RECIST version 1.1. OS was estimated using the Kaplan-Meier method.

Results

Totally 18 pts had a median age of 74 years (range: 46–90), with 83.3% and 16.7% having ECOG 0–1 and 2–3. The bladder and the upper urinary tract were primary tumor sites in each 50% of pts. Most pts (77.8%) had ≥1 visceral metastasis. Most pts (9/12) on EV+P had no prior treatments. In pts on EV mono (n=6), 66.7% and 33.3% had 2 and ≥3 prior lines of treatments. Pts on EV+P and EV mono had median EV cycles of 4.5 (1–10) and 3 (1–8) and ORRs of 75% and 33.3%. Two (16.7%) pts on EV+P had complete response. TRAEs led to 38.9% of EV interruptions, 33.3% of dose reductions, and 5.56% of discontinuations. Any-grade TRAEs occurred in 88.8% of pts (pruritis: 77.8%; peripheral neuropathy: 66.7%; rash: 50%). Three pts (16.7%; EV+P: 2; EV mono: 1) had Grade ≥3 rash. The 6-month OS rate was 70% (mean follow-up, 2.11 months).

Conclusions

Our preliminary real-world data showed promising antitumor activities of EV±P in Asian mUC pts. EV+P appeared to yield a higher ORR vs. EV mono. Skin toxicities (pruritis and rash) were major concerns in our cohort, highlighting a unique EV tolerability profile in Asian pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.